Home › Compare › BVTEF vs MRK

BVTEF vs MRK: Dividend Comparison 2026

BVTEF yields 9389.67% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BVTEF wins by $29652364190233612.00M in total portfolio value
10 years
BVTEF
BVTEF
● Live price
9389.67%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29652364190233612.00M
Annual income
$29,043,889,991,112,714,000,000.00
Full BVTEF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — BVTEF vs MRK

📍 BVTEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBVTEFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BVTEF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BVTEF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BVTEF
Annual income on $10K today (after 15% tax)
$798,122.07/yr
After 10yr DRIP, annual income (after tax)
$24,687,306,492,445,807,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, BVTEF beats the other by $24,687,306,492,445,807,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BVTEF + MRK for your $10,000?

BVTEF: 50%MRK: 50%
100% MRK50/50100% BVTEF
Portfolio after 10yr
$14826182095116806.00M
Annual income
$14,521,944,995,556,357,000,000.00/yr
Blended yield
97.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BVTEF
No analyst data
Altman Z
-12.4
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BVTEF buys
0
MRK buys
0
No recent congressional trades found for BVTEF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBVTEFMRK
Forward yield9389.67% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$29652364190233612.00M ✓$30.7K
Annual income after 10y$29,043,889,991,112,714,000,000.00 ✓$950.29
Total dividends collected$29611830854875112.00M ✓$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BVTEF vs MRK ($10,000, DRIP)

YearBVTEF PortfolioBVTEF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$949,667$938,967.14$11,192$351.54+$938.5K → BVTEF
2$84,353,175$83,337,030.95$12,524$392.70+$84.34M → BVTEF
3$7,008,317,024$6,918,059,127.47$14,015$438.65+$7008.30M → BVTEF
4$544,670,195,710$537,171,296,494.19$15,682$489.96+$544670.18M → BVTEF
5$39,599,349,640,156$39,016,552,530,745.70$17,547$547.23+$39599349.62M → BVTEF
6$2,693,431,305,051,366$2,651,060,000,936,399.50$19,632$611.16+$2693431305.03M → BVTEF
7$171,402,817,083,723,070$168,520,845,587,318,100.00$21,963$682.53+$171402817083.70M → BVTEF
8$10,206,035,765,188,530,000$10,022,634,750,908,946,000.00$24,571$762.18+$10206035765188.51M → BVTEF
9$568,667,475,813,928,340,000$557,747,017,545,176,500,000.00$27,486$851.08+$568667475813928.38M → BVTEF
10$29,652,364,190,233,613,000,000$29,043,889,991,112,714,000,000.00$30,745$950.29+$29652364190233612.00M → BVTEF

BVTEF vs MRK: Complete Analysis 2026

BVTEF — Stock

Iconic Minerals Ltd., a mineral exploration company, engages in the acquisition and exploration of gold and lithium properties in Nevada and Canada. The company holds a 100% interest in the Hercules project located in Lyon County; and 50% interests in the New Pass project located in Churchill County and Squaw creek property located to the north of Battle Mountain in Nevada. It also holds a 100% interest in the Bonnie Claire property with 1,155 claims covering 13,900 acres located in Nevada; and holds an option to acquire a 100% interest in Smith Creek property located in Nevada. The company was formerly known as Bonaventure Enterprises Inc. and changed its name to Iconic Minerals Ltd. in March 2011. Iconic Minerals Ltd. was incorporated in 1979 and is headquartered in Vancouver, Canada.

Full BVTEF Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this BVTEF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BVTEF vs SCHDBVTEF vs JEPIBVTEF vs OBVTEF vs KOBVTEF vs MAINBVTEF vs JNJBVTEF vs ABBVBVTEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.